Category: clinical study retractions

“This is something that we have never seen before in any study:” Group loses two more papers

Alexandria University, via Wikimedia

A group of rheumatology researchers in Egypt that lost a paper in 2016 for a variety of problems has lost two more.

The authors common to the two papers, Anna Abou-Raya and Suzan Abou-Raya, are based at the University of Alexandria, which did not find evidence of scientific misconduct, according to one of the retraction notices. The journal that published the two papers, The Journal of Rheumatology, however, found several other issues that led them to retract the papers.

Among them was that for one of the studies to have proceeded as described, all 125 subjects would have had to been enrolled and randomized on a single day: Continue reading “This is something that we have never seen before in any study:” Group loses two more papers

OSU cancer researcher who has faced misconduct allegations sues to regain lost department chairmanship

Carlo Croce

Carlo Croce, the embattled cancer researcher at The Ohio State University (OSU), is suing the institution to reclaim the department chair he lost late last year for reasons that he says are unclear.

In a filing with the Franklin County civil court, Croce and his attorneys, from the Columbus firm of James E. Arnold and Associates, argue that the university failed to follow its own rules for demoting faculty members last year when it stripped Croce of his position of chair of the Department of Cancer Genetics and Biology. Croce had held the post for more than three consecutive four-year terms, starting in October 2004.

The nut of Croce’s claim centers on the alleged failure of K. Craig Kent, the university’s Dean of the College of Medicine, to consult with the college’s faculty members before demoting him in early November 2018 — a move Croce opposed. Continue reading OSU cancer researcher who has faced misconduct allegations sues to regain lost department chairmanship

Anversa cardiac stem cell lab earns 13 retractions

Piero Anversa

Two months after Harvard and the Brigham and Women’s Hospital said they were requesting the retraction of more than 30 papers from a former cardiac stem cell lab there, two American Heart Association journals have retracted more than a dozen papers from the lab.

Yesterday, Circulation retracted three papers, and Circulation Research retracted 10. All 13 were among 15 subjected to expressions of concern last month. Continue reading Anversa cardiac stem cell lab earns 13 retractions

Dental researcher in Spain up to 18 retractions

Jose Luis Calvo-Guirado

A researcher in Spain who studies dental implants has had another six papers retracted, for a total of 18.

José Luis Calvo-Guirado‘s latest retraction, which along with the other 17 appeared in Clinical Oral Implants Research, a Wiley title, was for “image discrepancies resulting in unreliable data.” Three appeared in June, and two in July, also for image issues. The researcher also has at least two corrections; one  in Annals of Anatomy — Anatomischer Anzeiger and one in Materials. Continue reading Dental researcher in Spain up to 18 retractions

Journals stamp expressions of concern on 15 papers from Anversa’s cardiac stem cell lab

Piero Anversa

More than four and a half years after questions were first raised about work in a cardiac stem cell lab at Harvard and the Brigham and Women’s Hospital, a year and a half after the Brigham and Partners Healthcare paid $10 million to settle allegations of fraud in the lab’s data, a month after Harvard the Brigham disclosed that they were calling for the retractions of more than 30 papers from the lab, and three weeks after the NIH paused a clinical trial based on the work, two leading journals have issued an expression of concern about 15 papers from the lab.

But expressions of concern are not retractions, of course. From the notice, in Circulation and Circulation Research, both of which are published by the American Heart Association: Continue reading Journals stamp expressions of concern on 15 papers from Anversa’s cardiac stem cell lab

Ketamine for depression? Paper retracted for error that double-counted clinical trial participants

A psychiatry journal has retracted a 2015 meta-analysis on the effectiveness of ketamine for depression after readers found that the article double-counted patients in some studies, thereby inflating the apparent benefits of the drug.

The article, “Efficacy of ketamine in bipolar depression: systematic review and meta-analysis,” was published in the Journal of Psychiatric Practice by a group from the United States and England. But a pair of researchers in Sweden noticed the duplication — and what seems to have been a rather slapdash approach to the work — and pushed to have the paper retracted.

According to the results section of the abstract: Continue reading Ketamine for depression? Paper retracted for error that double-counted clinical trial participants

In a first, U.S. CDC retracts, replaces study about suicide risk in farmers

In a first for the CDC, the agency’s premier scientific publication has retracted a 2016 article on suicide, five months after a news story pointed out serious errors in the paper.

The article, initially published as “Suicide Rates by Occupational Group — 17 States, 2012,” had purported to find that farmers were at particularly high risk of suicide. That result in particular caught the attention of a website called The New Food Economy (TNFE), which last June called out what it said were errors in the CDC’s analysis. And on June 29, the journal, the Morbidity and Mortality Weekly Report (MMWR), issued a reader’s note.

As TNFE wrote, the crux of the mistake involves the misclassification of farmer suicides in a way that significantly inflated the rate of these events — errors the website said it first raised with the CDC in April 2018: Continue reading In a first, U.S. CDC retracts, replaces study about suicide risk in farmers

A convicted felon writes a paper on hotly debated diets. What could go wrong?

Richard Fleming

Pro-tip for journals and publishers: When you decide to publish a paper about a subject — say, diets — that you know will draw a great deal of scrutiny from vocal proponents of alternatives, make sure it’s as close to airtight as possible.

And in the event that the paper turns out not to be so airtight, write a retraction notice that’s not vague and useless.

Oh, and make sure the lead author of said study isn’t a convicted felon who pleaded guilty to healthcare fraud.

If only we were describing a hypothetical. Continue reading A convicted felon writes a paper on hotly debated diets. What could go wrong?

Caveat scriptor: How a journal editor unraveled the mystery of the overlapping bad data

John Loadsman

Caveat scriptor—writer beware.

That’s the moral of a recent editorial in the Saudi Journal of Anesthesia, prompted by the retraction in that journal of a 2014 paper with bum data.

The editorial was written by John Loadsman, an anesthesiologist in Sydney, Australia, and editor of the journal Anaesthesia and Intensive Care, who played a role in the retraction. Here’s how.

According to Loadsman, he was considering an article for his journal — a meta-analysis of previously published findings. On inspection, he he noticed that some of the studies cited in the meta-analysis were potentially problematic, including Continue reading Caveat scriptor: How a journal editor unraveled the mystery of the overlapping bad data

The “regression to the mean project:” What researchers should know about a mistake many make

David Allison, via IU

The work of David Allison and his colleagues may be familiar to Retraction Watch readers. Allison was the researcher — then at the University of Alabama, Birmingham, now at Indiana University — who led an effort to correct the nutrition literature a few years ago. He and his colleagues are back, this time with what might be called the “Regression to the Mean Project,” an attempt to fix a problem that seems to vex many clinical trials. You may have noticed some items in Weekend Reads about letters to the editor that mention the issue. Here, Allison explains.

•Retraction Watch (RW): First, what is “regression to the mean,” and what does it mean for clinical studies? Continue reading The “regression to the mean project:” What researchers should know about a mistake many make